gemcitabine has been researched along with 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, P; Dealwis, CG; Harris, ME; Huff, SE; Mohammed, FA; Pink, J; Viswanathan, R; Yang, M | 1 |
| de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL | 1 |
| Clairmont, C; Doroshow, J; Fishman, M; Johnson, B; Margolin, K; Sullivan, D; Sznol, M; Yen, Y | 1 |
| Bergman, AM; Hoebe, EK; Kamphuis, JA; Laan, AC; Peters, GJ; Sigmond, J | 1 |
| Hirte, H; Johnson, C; Low, J; Mackenzie, MJ; Moore, MJ; Pond, G; Saltman, D | 1 |
| Chan, AT; Goh, BC; Lam, KC; Leong, SS; Ma, B; Mo, F; Mok, T; Soo, R; Tan, EH; Wang, LZ; Zee, B | 1 |
| Attia, S; Eickhoff, J; Erlichman, C; Heun, J; Holen, KD; Huang, W; Kolesar, J; Laheru, D; Mahoney, MR; Pitot, HC | 1 |
| Bayer, GK; Graham, DL; Kolesar, JM; Lee, JW; Mazurczak, M; Schiller, JH; Tate, JM; Thomas, SP; Traynor, AM | 1 |
| Christos, P; Espinoza-Delgado, I; Hamel, N; Kaubish, A; Lane, ME; Matulich, D; Ocean, AJ; Siegel, A; Sparano, JA; Sung, M; Ward, MM; Yen, Y | 1 |
| Bekaii-Saab, T; Deam, D; Grever, MR; Harper, EJ; Hicks, WJ; Ivy, SP; Ling, Y; Liu, X; Liu, Z; Martin, LK; Monk, JP; Mortazavi, A; Otterson, GA; Phelps, MA; Wei, L; Wu, X; Yen, Y; Zhou, BS | 1 |
| Alyahya, MY; Bhadra, S; Khan, S; Samuel, RE; Xu, YJ | 1 |
1 review(s) available for gemcitabine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
| Article | Year |
|---|---|
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Drug Discovery; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Thiazoles; Thiazolidines; Thiosemicarbazones | 2019 |
7 trial(s) available for gemcitabine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
| Article | Year |
|---|---|
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methemoglobinemia; Middle Aged; Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones | 2004 |
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Failure | 2007 |
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gemcitabine; Humans; Hypoxia; Leukocytes, Mononuclear; Lung Neoplasms; Male; Methemoglobinemia; Middle Aged; Pyridines; Thiosemicarbazones; Treatment Outcome | 2008 |
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukopenia; Male; Middle Aged; Mouth Mucosa; Pancreatic Neoplasms; Polymorphism, Genetic; Pyridines; Ribonucleoside Diphosphate Reductase; Survival Rate; Thiosemicarbazones; Treatment Outcome | 2008 |
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Pyridines; Survival Analysis; Thiosemicarbazones; Time Factors; Treatment Outcome | 2010 |
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Fine-Needle; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatic Insufficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Pyridines; Ribonucleotide Reductases; RNA, Messenger; Survival Analysis; Thiosemicarbazones | 2011 |
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Ribonucleoside Diphosphate Reductase; Thiosemicarbazones; Thrombocytopenia | 2013 |
3 other study(ies) available for gemcitabine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
| Article | Year |
|---|---|
Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Topics: Chemistry Techniques, Synthetic; Enzyme Inhibitors; Humans; Hydrazones; Molecular Docking Simulation; Protein Conformation; Ribonucleotide Reductases; Structure-Activity Relationship | 2018 |
The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; DNA; Drug Synergism; Gemcitabine; Humans; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Tumor Cells, Cultured | 2007 |
Replication stress induced by the ribonucleotide reductase inhibitor guanazole, triapine and gemcitabine in fission yeast.
Topics: Cell Cycle Proteins; Checkpoint Kinase 2; Deoxycytidine; DNA Replication; Enzyme Inhibitors; Gemcitabine; Guanazole; Humans; Hydroxyurea; Pyridines; Ribonucleotide Reductases; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Thiosemicarbazones | 2022 |